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Anterior ischemic optic neuropathy (AION) is due to optic nerve head ischemia, and there is currently no
effective treatment. Age is a signiﬁcant risk factor for both arteritic and nonarteritic AION (NAION),
although we do not fully understand the changes that occur in aging that lead to selective vulnerability of
the optic nerve head. Arteritic AION, which is most often seen in the setting of giant cell arteritis, is
caused by vasculitis and thromboembolism of the ophthalmic circulation leading to impaired perfusion
of the short posterior ciliary artery and infarction of the optic nerve head. More commonly, AION is
nonarteritic, and vision loss is typically altitudinal and noted most commonly upon awakening. NAION
has been associated with a variety of risk factors, including disc-at-risk, vascular risk factors including
diabetes, vasospasm and impaired autoregulation, nocturnal hypotension, and sleep apnea. This review
summarizes the clinical presentation of non-arteritic AION and arteritic AION associated with giant cell
arteritis and the current and future treatment approaches for human NAION based on lessons from
photochemical thrombosis models of NAION.
Copyright  2013, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Anterior ischemic optic neuropathy (AION) is the most common
acute optic neuropathy in adults older than 50 years old, and it
typically leads to irreversible vision loss.1e4 AION is subdivided into
arteritic and non-arteritic types. About 10% of patients with AION
have the arteritic type, whereas the non-arteritic type (NAOIN)
accounts for the majority of cases. AION is due to ischemia of the
optic nerve head, which is a watershed zone and therefore
vulnerable to changes related to vascular risk factors and
compartment syndrome. The incipient event involves acute
ischemia of the prelaminar, and, in particular, the laminar and
retrolaminar optic nerves due to reduced perfusion in the circle of
ZinneHaller, with the short posterior ciliary arteries thought to
contribute most signiﬁcantly.4 The pathogenesis of arteritic AION is
thought to arise from vasculitis leading to stenosis and thrombo-
embolism involving the ophthalmic, central retinal artery, andy have no ﬁnancial or non-
tter or materials discussed in
mology, Stanford University
03-5353, USA.
e Ophthalmologic Society of Taiwespecially the short posterior ciliary artery. Although the patho-
genesis of NAION is not well understood, vascular, anatomic, and
other risk factors are involved.1,3,4 Some medications such as
amiodarone, phosphodiesterase type 5 inhibitors such as sildenaﬁl,
and interferon-a have been associated with NAION. Age is a leading
risk factor in both arteritic and nonarteritic AION as well as in
glaucoma, suggesting that the process of normal aging may play a
role in increasing the susceptibility of central axons.5
We are particularly interested in an AION animal model
because: (1) AION is easily and well modeled in rodents using
photochemical thrombosis to induce localized optic nerve head
ischemia; (2) acute injury of the central nervous system is poten-
tially better timed and more amenable to therapeutic intervention
than a slowly progressive condition such as glaucoma; (3) there is
currently no effective treatment for AION; and (4) ischemia plays a
role in other optic neuropathies such as glaucoma and papilledema,
so ﬁndings in AION are also potentially signiﬁcant to other causes of
retinal ganglion cell (RGC) loss.
This review summarizes the state of our understanding in the
clinical presentation and treatment of AION with particular
emphasis on lesson learned from photochemical thrombosis ani-
mal models and their implications on designing future treatment
modalities.an. Published by Elsevier Taiwan LLC. All rights reserved.
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2.1. Clinical presentation
NAION is the most common type of AION.4 Historically, NAION
was reported in Europe during the 19th century but was not
recognized until the 1960s and 1970s.1,2,6,7 Patients typically pre-
sent upon awakening with altitudinal visual ﬁeld defects, relative
afferent pupillary defects from unilateral involvement, optic disc
edema, and narrowing of the peripapillary retinal arterioles (Fig. 1).
Optical coherence tomography (OCT), which uses light interfer-
ometry to visualize in vivo retinal layers and anatomic changes, has
revealed acute retinal nerve ﬁber layer swelling and thinning over a
period of months.8e11 The macular ganglion cell complex (GCC),
which measures the total thickness of the ganglion cell layer and
the inner plexiform layer, estimates irreversible RGC loss over time.
2.2. Incidence and risk factors
The incidence of NAION in the USA is 2.3e10.2/100,000 or
1500e6000 new cases/year. The most signiﬁcant risk factors for
NAION include: crowded disc (so-called disc-at-risk), diabetes,
atherosclerosis, age, and sleep apnea. Arguably, the most modiﬁ-
able risk factor after the diagnosis of NAION is sleep apnea. In one
study of 635 patients (871 eyes or 925 episodes), 73% note visionFig. 1. An 89-year-old Caucasian woman presented upon awakening with left eye visual ﬁel
left eye shows optic disc swelling, splinter hemorrhage, and narrowing of the peripapillary
optic neuropathy exhibits optic nerve pallor and narrowing and irregularity of the peripap
than superior visual ﬁeld loss. (D) Spectral-domain optical coherence tomography shows sign
eye; OS ¼ left eye.loss soon after awakening.12 This may be related to a combination
of nocturnal hypoxemia and hypotension. Systemic hypotension
from shock or certain type of prolonged surgery is signiﬁcantly
associated with AION.13 Other reported risk factors include cataract
or other ophthalmic surgeries,14,15 and the use of phosphodies-
terase type 5 inhibitors.16e19
2.3. Pathogenesis and treatment of human NAION
The pathogenesis of human NAION is unclear. Important players
include vascular factors (diabetes, nocturnal hypotension, athero-
sclerosis, failure of autoregulation, increased resistance from rela-
tively elevated IOP), hypoxemia (sleep apnea), and compartment
syndrome (disc-at-risk, congenital optic nerve hypoplasia). There
are relatively few research studies designed to perturb these factors
to determine how they contribute to AION or how their alteration
may impact outcome.
There are some data suggesting that inﬂammation may play a
role in human NAION. In one valuable case of human autopsy ob-
tained 20 days after the onset of vision loss from NAION, there was
an accumulation of Iba1þ/ED1þ cells or extrinsic macrophages in
ischemic areas of the optic nerve and a presence of Iba1þ/ED1 cells
or intrinsic microglia in the area of ischemia and the penumbra.20
Proinﬂammatory cytokines are involved in thrombotic events
such as myocardial infarction and stroke, and they may play a roled loss due to non-arteritic anterior ischemic optic neuropathy. (A) Fundus photo of the
arterioles. (B) Fundus photo of the left eye 1 year after non-arteritic anterior ischemic
illary arterioles. (C) Humphrey visual ﬁeld study of the left eye reveals inferior greater
iﬁcant retinal nerve ﬁber layer thinning of the left eye (shown on the right). OD ¼ right
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is associated with elevated interleukin (IL)-8 but normal levels of
IL-6 and tumor necrosis factor-a (TNF-a).21 Thesemarkers have also
been shown to be elevated in patients with central retinal artery
occlusion.22 Plasma levels of IL-6 and IL-8 are signiﬁcantly elevated
after central retinal artery occlusion, especially within 6 hours
of onset.22,23 Although NAION patients typically have normal
erythrocyte sedimentation rate, one study of 33 NAION patients
reveals that NAION patients have slightly higher erythrocyte sedi-
mentation rate on average than normal controls (p ¼ 0.025),
sometimes necessitating a temporal artery biopsy as part of the
diagnostic evaluation.24 NAION patients also have a higher level of
highly sensitive C-reactive protein.24 These ﬁndings in a small
number of patients support the idea that inﬂammation plays a role
after ischemia, and more studies are necessary to determine if
biomarkers of inﬂammation are important in human NAION.
With a relative lack of understanding of disease mechanisms, it
is no surprise that there is no effective treatment for NAION. One
area of controversy in the treatment of NAION is the use of corti-
costeroids in acute NAION. On the one hand, there is some evidence
that inﬂammation plays a role in human AION (see above), and the
idea of decreasing swelling and minimizing worsening of
compartment syndrome seems sound. On the other hand, the ef-
ﬁcacies of corticosteroids are not spectacular, probably at least
partly because they are given too late. Also, corticosteroids have
known side effects, andwe cannot rule out that corticosteroids may
suppress some inﬂammatory responses that are beneﬁcial. The lack
of clinical trial data means we may never know if corticosteroids
work or not.
Although anti-VEGF therapy has been shown to inhibit inﬂam-
matorymolecules and reduce edema, there is a potential concern of
inducing further vascular compromise in an eye that is already at aFig. 2. A 77-year-old Caucasian man presented with amaurosis fugax followed by persistent
(A) Fundus photo of the left eye within days of the onset with inferior pallid optic disc ed
ischemia. (B) Fluorescein angiography of the left eye within days of the onset shows choroid
eye 8 years prior to anterior ischemic optic neuropathy, which is shown for comparison. (Dcritical or threshold level of perfusion.25 Regarding these thera-
peutic options, there is no well-designed study or clinical trial that
shows a signiﬁcant beneﬁt, and treatment is at the discretion of the
physician.
There has been a small number of clinical trials involving
treatment of human NAION, including the ischemic optic neurop-
athy decompression trial, which shows no beneﬁt in surgical
treatment of the compartment syndrome.26,27 Atkins et al25 pro-
vides an excellent review on the key approaches in the treatment of
human NAION and therapeutic interventions addressing vasoactive
mechanisms, potential thrombosis, decreasing optic disc edema,
decompression, neuroprotection, and others.
3. Arteritic AION and giant cell arteritis
Arteritic AION is an ophthalmic emergency because it is asso-
ciated with a signiﬁcant risk of bilateral involvement and rapid
progression of vision loss.28 The risk of bilaterality in patients with
arteritic AION is 1.9 times that of NAION patients.29 In arteritic
AION, there is typically a signiﬁcant decrease in visual acuity, alti-
tudinal or generalized visual ﬁeld loss, pallid optic disc edema,
narrowing of the peripapillary arterioles, and sometimes choroidal
or retinal ischemia (Fig. 2). Arteritic AION is most commonly
associated with giant cell arteritis, also known as temporal arteritis.
Giant cell arteritis is a systemic vasculitis syndrome leading to
stenosis and thromboembolism affecting the medium and large
arteries, especially the temporal, cervical, vertebral, and coronary
arteries, as well as the aorta and its branches. In arteritic AION,
doppler studies have shown signiﬁcantly reduced central retinal
and short posterior ciliary arterial mean ﬂow velocities.30
Depending on the location of stenosis or occlusion, there can be
high velocity, turbulent, or reversal of ﬂow within the ophthalmicsuperior vision loss in the left eye due to arteritic anterior ischemic optic neuropathy.
ema. There is a ribbon of whitening just superior to the disc due to nerve ﬁber layer
al hypoperfusion most notably in the temporal periphery. (C) Fundus photo of the left
) Humphrey visual ﬁeld of the left eye showing superior visual ﬁeld loss.
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AION, central retinal artery occlusion, choroidal and submacular
choroidal ischemia, posterior ischemic optic neuropathy, ocular
ischemic syndrome, and anterior segment ischemia. Cerebral artery
involvement can lead to stroke, and ischemia of the orbit, cranial
nerves 3, 4, 6, or brainstem can lead to binocular diplopia.
3.1. Incidence, geography, risk factors, and treatment of giant cell
arteritis
The most important risk factors for giant cell arteritis include
age,31 female sex, HLA-DR4 major histocompatibility haplotype,
and Caucasian ethnic origin.32,33 Geographically, giant cell arteritis
is most commonly found in Scandinavia and Iceland, where the
incidence can be as high as 20.4 and 27/100,000 for those older
than 50 years.34 African Americans and Asians have relatively
lower risk of giant cell arteritis.34e37 In one Japanese study of 690
cases by questionnaire, the prevalence of giant cell arteritis was
1.47/100,000 people older than 50 years.34,35,38 In a study of 38
patients with biopsy-proven giant cell arteritis, 2.6% (one) is Asian
compared with 82% (31) Caucasian.37 Once conﬁrmed on biopsy,
the mainstay of treatment for giant cell arteritis is long-term
corticosteroid therapy with consideration of steroid-sparing
agents, typically for months to years.32,39
4. Animal models of AION
4.1. Photochemical thrombosis model of AION
The best animal model for AION is the photochemical throm-
bosis model.40 It is not arteritic, and it utilizes laser as a low energy,
focused light source to induce optic nerve head ischemia immedi-
ately following intravenous tail vein injection of rose bengal.41 Rose
bengal is a derivative of ﬂuorescein dye. When the laser light shines
on the optic disc immediately following dye injection, platelet ag-
gregation, and thrombosis of the arterioles that supply the optic
discs occur, with relative sparing of the more superﬁcial larger
caliber central retinal vessels.41 Since the ﬁrst photochemical
thrombosis model of AION in rats in 2003,41 this model has been
successfully used in rats,41e44 mice,11,45e47 and primates.20,48
4.2. Differences between human and experimental AION
The photochemical thrombosis model is superior to the vascular
occlusion model of posterior ciliary artery, optic nerve crush, optic
nerve transection, retinal ischemia, N-methyl-D-aspartate-induced
retinal ganglion cell excitotoxicity, and glaucoma or other optic
neuropathy models because the mechanism is ischemic, the area
involved is localized, and the technique is easy to perform rapidly
and consistently in different species and across various labora-
tories. Direct comparison of murine AION and optic nerve crush
reveal that AION leads to relatively less severe RGC loss compared
with the optic crush model.46
Although this model is the best we have, the photochemical
thrombosis model is still limited in many ways, because: (1) this
model involves global optic disc ischemia and human NAION is
often partial; (2) there are species differences in blood supply to the
optic nerve head49; (3) in the animal model, ischemia is induced
from the front of the eye in a transpupillary fashion, whereas hu-
man AION is a result of ischemia in the post-laminar or laminar
region; (4) there is no evidence that human NAION is caused by
thrombosis; (5) many animals used do not have a rigid lamina or
the same anatomic factors that would contribute to compartment
syndrome; and (6) animals used for the study are typically young
adults rather than age-equivalent to 50-year-old humans.4.3. Issues with mouse as an animal model
Other than the imperfection of animal models, there are also
several issues speciﬁc to the use of mouse as an animal model.
Although the explosion of available transgenic and knockout mice
makes mouse an attractive animal in vision research in general,
there are reports that describe retinal problems identiﬁed in
seemingly normalmice.50 In a study of over 450mice fromdifferent
genetic backgrounds including C57BL/6J, BALB/cJ, and transgenic or
knockout mouse strains, the authors use fundus photography,
confocal laser scanning ophthalmoscopy, and OCT to document
abnormal eye ﬁndings. These include retinal drusen, vascular
malformations, hyaloid vessel remnants, retinal pigment epithe-
lium abnormalities, and cataracts. The frequency of abnormalities
ranged from 1.5% in C57BL/6J mice to 100% in BALB/cJ mice in in
2e4-month-old mice. Exclusion of the BALB/cJ mice leads to
average incidence of 5.7% or about one in every 20 mice. The
presence of retinal drusens and cataract are more common in mice
that are older than 1 year (M.A. Shariati and Y.J. Liao, unpublished
observation), which is the equivalent of human age 42.5 years. In
the study by Bell et al,50 the incidence of retinal abnormalities
increases from 1.5% in 2e4-month-old mice to 5.9% in 6e14-
month-old in the C57BL/6J strain.
Another report identiﬁes an inbred Rd8 mutation in the Crb1
gene in homozygous forms in C57BL/6N mice from many common
commercial vendors.51 This mutation results in retinal degenera-
tion with many retinal drusen, and is not present in the C57BL/6J
substrain, which is found to have relatively low incidence of eye
abnormalities.50 The Rd8 mutation is present in ES cells derived
from C57BL/6N, so it is present in transgenic and knockout mice
made using C57BL/6N embryos or C57BL/6N-derived ES cells.51
There are several ways to avoid experimental complications
due to these issues: (1) use genetic strains that do not have
known mutation; (2) perform in vivo imaging of the mouse at
baseline to screen for issues prior to experimental intervention;
and (3) use a relatively larger number of animals so elimination
of data due to experimentally unrelated issues does not result in
problems with statistical analysis. Finally, the use of mouse to
study short-term changes in the retina, especially changes
related to RGCs or the optic nerve may be relatively spared from
these complications.5. Results of experimental AION studies
Despite the caveats of the photochemical thrombosis model of
AION, this model has been highly valuable in studying the acute
and chronic changes following optic nerve head ischemia. There is
evidence that, following experimental AION, there is a complex set
of likely simultaneous events involving changes in the RGC cell
body, axons, optic nerve oligodendrocytes, local and extrinsic
microglia, and the inﬂammatory cascade.5.1. Within hours and a few days after AION
5.1.1. Capillary drop out
Immediately after experimental AION, there is visible whitening
of the optic disc consistent with ischemia. Using India ink intra-
cardiac perfusion, several reports show that there is loss of the ﬁne
capillaries within the disc.41,44,45 Interestingly, one study uses FITC-
BSA perfusion and confocal imaging to show that there is minimal
optic disc capillary dropout at 4 hours after ischemia and more
dramatic loss at 1 day, suggesting the therapeutic window may be
longer than 3 hours, which is typical of gray matter ischemia, but
less than 24 hours.52
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One day after AION, ﬂuorescein angiography in rodent AION and
ICG angiography in primate AION reveal there is prominent stain-
ing of the optic disc due to leakage of the peripapillary ves-
sels,11,41,43,45 which is similar to what has been seen in human
NAION.53 The breakdown of the nerve-blood barrier following
AION has also been demonstrated on a cellular level. One day after
rodent AION, there is diffuse immunoglobulin (Ig)G staining of the
optic nerve head from the breakdown of the nerve-blood barrier
and extravasation of serum protein.52 This leaky blood-nerve bar-
rier is well demonstrated using exogenous IgG or different molec-
ular weight size dyes.52 Although this optic disc leakage resolves
within days in the rodent AION, in the primate AION, optic disc
staining on Indocyanine green (ICG) angiography lasts for 2 weeks,
suggesting that there may be persistent inﬂammation and edema,
which can theoretically continue to cause further damage.20,48
Similar to the more prolonged inﬂammation and swelling seen in
primate AION, a human pathologic study 20 days after AION reveals
there is persistent evidence of inﬂammation.20,48 There is certainly
amble evidence in serial human OCT studies after AION that the
optic disc swelling takes weeks to resolve.8e10
5.1.3. Optic nerve head swelling
One day after experimental AION, the optic nerve head is
swollen,11,41,43e45,48 and there is often subretinal ﬂuid spillover in
the peripapillary potential space (YJ Liao, unpublished data). This
phenomenon has been reported in human NAION.54 OCT 12 cir-
cular scan [also known as retinal nerve ﬁber layer (RNFL) scan] and
measurement of the ganglion cell complex (GCC) which includes
the nerve ﬁber layer, ganglion cell layer, and the inner plexiform
layer, reveal that there is about 30% swelling of the GCC 1 day after
AION compared with control eyes. There is also swelling of the
outer retina at 1 day, probably from a combination of bystander
effects and wrinkling of the nuclear layers due to a displacement
from the swollen optic nerve.11 This swelling may be a combination
of vasogenic edema from the breakdown of nerve-blood barrier and
cytotoxic edema. There is histologic evidence of axonal swelling in
the optic nerve using electron microscopy.41,45 Axonal transport is
signiﬁcantly disrupted within 1 day after occlusion of the short
temporal posterior ciliary artery55 and after experimental AION (J.
Ma, Y.J. Liao, unpublished data). This disruption contributes to optic
nerve head swelling, but, more signiﬁcantly, it also means there is a
severe impairment of anterograde and retrograde transport of
neurotrophic factors and other important survival cues. Function-
ally, at 1e2 days after AION, visual evoked potential amplitudes are
already signiﬁcantly diminished at 1 day .41,44,47
5.1.4. Loss of oligodendrocytes
Damage of the optic nerve oligodendrocytes and RGC axons
occurs within days, prior to a signiﬁcant loss of RGCs.45,46 These
changes extend anterogradely toward the optic chiasm and the
brain.45,46 Apoptosis of the oligodendrocytes as seen by TUNEL (ter-
minal deoxynucleotidyl transferase dUTP nick end labeling) stain is
observed as early as a few days after AION and progresses over
days.45,46 Demyelination is seen simultaneous by Luxol-fast blue
stain of the optic nerve and transmission electron microscopy.45,46
5.1.5. Inﬂammatory response
In rodent AION, there is evidence of an early postischemia in-
ﬂammatory response. There is microglial activation as measured by
the density of Iba-1þ cells at the optic nerve head.47,48 In primates,
AION, the Iba-1þ cells are located at the prelaminar and laminar re-
gion but also at the postlaminar optic nerve. In primate AION, this
inﬂammatory phenomenon lasts for 2 weeks, which raises the
question of their role in the vicious cycle of further axonal loss due tobystander effect.20,48 Other thanmicroglial activation, there is also an
upregulation of proinﬂammatory cytokines including plasma and
optic nerve IL-6, TNF-a, and macrophage inﬂammatory protein-2.56
5.1.6. Limited early RGC loss
Within days after AION, there is relatively little RGC death, and
few cells in the ganglion cell layer stain positive for TUNEL.46
However, there is already evidence of diffuse RGC stress as
evident by c-fos-LacZ expression in a transgenic animal, which may
correlate with cell death chronically.57
5.2. First week after AION
OCT shows that the optic nerve head swelling improves at 4e5
days after AION.11,41 However, this is just the beginning of axon-
opathy and RGC loss. Within the ﬁrst week after AION, there is
axonal edema and collapse in the optic nerve axons.41 Primate
models of AION show that there is tissue edema and hemorrhage
for up to 1 week postischemia, consistent with reperfusion injury.
This swelling increases within the ﬁrst week and persists for 2e3
weeks,48 and edema may result in compression of initially spared
axons, causing secondary axonal defects.
5.3. Chronic AION
5.3.1. RGC axonal loss
Withinweeks after AION, there is pallor and atrophy of the optic
nerve head.41 OCT study shows about 30% thinning of the GCC.11
Optic nerve axons are lost in a variable pattern and range from
25% to 60% in murine AION. The central optic nerve axons are more
severely affected than the periphery,41,45,46,57 due to the way AION
is induced. Oligodendrocyte number also decreases signiﬁcantly.46
5.3.2. RGC loss via apoptosis
RGC layer cells, which include RGCs and displaced amacrine
cells, are lost.41,43,44 Consistent with the loss of RGCs, the expression
of Brn3, a marker for RGCs, decreases,41 RGC loss peaks at 2e3
weeks after AION and is thought to be via apoptosis through acti-
vation of the caspase pathway.42,45,57e59
5.3.3. Three-week therapeutic window in experimental AION
We know from AION animal studies that RGCs are irreversibly
lost 3 weeks after AION, so this is the upper end of the therapeutic
window for all treatment of experimental AION except for cell
replacement therapy with stem cells. In both animals and humans,
there is also evidence of anterograde degeneration in chronic AION,
which can be trans-synaptic. This means that both the RGCs and
target neurons can be removed with surgical precision, posing
serious obstacles for cell-based therapy.60 This means that even if
we can reconstitute RGCs in the retina and send the axons down the
right way, there may be no retinoptic target neurons to make
connections, so early therapeutic intervention likely means better
therapeutic outcome.
6. Potential treatment for AION based on animal studies
The current state of treatment of patients with NAION includes a
multipronged approach to minimize further damage by correcting
nocturnal hypotension, treatment of sleep apnea, stopping drugs
with possible association with AION, and consideration of cortico-
steroid treatment or hyperbaric oxygen treatment. In the long term,
patients should address their vascular risk factors such as diabetes,
hypertension, and hyperlipidemia. The photochemical thrombosis
model has been useful to narrow down the therapeutic window of
intervention, which is at maximum up to 3 weeks in the rodent,
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of the retina.11 However, most treatment modalities probably do
not have such a generous window, and all therapeutic options are
likely to be more effective if instituted as early as possible.
Based on all studies to date and collectivewisdom of research on
thromboembolic diseases, many different classes of drugs have
been tested, although typically not in a rigorous clinical trials
format.25 Factors that contribute to this slow progress include: (1)
lack of understanding of the pathogenic mechanisms of human
AION andwhat interventionswill make themost impact andwhen;
(2) difﬁculties of translating our ﬁndings in animal studies to
humans; (3) inability to address major risk factors such as disc
anatomy and age; (4) the relative rarity of AION and low number of
patients who present for medical attention in time; and (5) a short
therapeutic window.
Based on animal studies, there are two obvious future di-
rections: targeting the anti-inﬂammatory pathways and promoting
survival of the remaining axons and RGCs. However, the likelihood
of success will remain unclear as long as human AION continues to
be an enigma.
6.1. Anti-inﬂammatory molecules
Several drugs have shown that modulation of the inﬂamma-
tory cascade leads to the successful treatment of experimental
AION. This is a logical choice and treatments targeting these
pathways that have been tried include systemic corticosteroids,
intravitreal triamcinolone, and intravitreal anti-VEGF therapy.
However, we know that the optic nerve is actually relatively
resilient to swelling or compartment syndrome alone, such as
from papilledema or optic disc drusen, and inﬂammatory or in-
fectious optic neuropathies often do not necessarily lead to
blindness. The tipping point is probably not isolated inﬂamma-
tion and accompanying vasogenic edema. It is likely to be
inﬂammation, which leads to rapidly worsening compartment
syndrome, and the concurrent phenomena of impaired vascular
autoregulation, ischemia-induced stasis of axoplasmic ﬂow, that
results in intra-axonal swelling, impaired axonal transport, loss
of neurotrophic support, stasis of intracellular organelles,
disruption of microtubules, and, ﬁnally, irreversible damage
causing retrograde RGC degeneration.8,61 The goal of anti-
inﬂammatory treatment is to extend the therapeutic window in
conjunction with an effective axon- or neuroprotective option,
and it should be given as early as possible.
6.1.1. QPI-1007
QPI-1007 is a synthetic small interference RNA that is designed
to inhibit the expression of caspase 2, which is activated following
retinal ischemia. According to its maker, QPI-1007 has signiﬁ-
cantly enhanced RGC survival in three different animal models. It
was used in a phase I clinical trial to assess the safety of intra-
vitreal injection and treatment following NAION, which is now
closed.
6.1.2. PGJ2
Prostaglandin J2 (PGJ2) dampens inﬂammatory responses and
has been found to be neuroprotective after stroke. Single, intrave-
nous injection of PGJ2 following rodent AION leads to increased
survival of Brn3þ RGCs 30 days later.52 This treatment is efﬁcacious
when given either immediately or 5 hours later. PGJ2 is thought to
decrease proinﬂammatory responses, and PGJ2 treatment has been
associated with dampening of NFkB activity, including suppression
of IL-1 and TNFa expression.52 Consistent with this idea, PGJ2
treatment is associated with a reduction of optic disc swelling on
OCT, which may enhance capillary perfusion.526.1.3. Alpha-B crystallin
Alpha-B crystallin is a small heat shock protein, like other a
crystallins, which have been shown to act as molecular chaperones
similar to Hsp70 and GroE,62 and it has been shown to be important
in central nervous system inﬂammation.63 Alpha-B crystallin has
been shown to be efﬁcacious in the treatment of the experimental
model of multiple sclerosis and optic neuritis.64 Treatment with
intravenous aB-crystallin leads to a signiﬁcant rescue of the oli-
godendrocytes and improvement in visual evoked potential la-
tencies but did not salvage the RGCs.47 This drug appears to be
protective toward oligodendrocytes and RGC axons and may be
useful as part of a cocktail of treatment for AION.
6.2. Neuroprotection
The key events leading to RGC degeneration have been most
intensely studied in animal models of glaucoma, although glau-
comatous optic neuropathy occurs at a much slower time scale.
Obstruction in axonal transport has been shown to be an early
event in the neuronal degeneration of the optic nerve.65e67 Quigley
et al68 show that the transport of brain-derived neurotrophic factor
(BDNF), a trophic factor for RGCs, and its receptor tropomyosin-
receptor kinase receptor B (TrkB), is impaired after acute eleva-
tion of intraocular pressure in rats, leading to loss of RGCs. These
are all worthy considerations although we do not know what are
the most critical issues when there is acute ischemia. There are
several endogenous neuroprotective molecules that are upregu-
lated after AION, including heat shock proteins 70, 84, and 8641,45
and small heat shock protein aB-crystallin.47 These heat shock
proteins are postulated to act as molecular chaperones that have
been shown to be protective in a variety of different conditions.
There is no evidence that a further increase of the level of
expression beyond the endogenous response will help. We would
be better off to identify what factors if missing, lead to increased
vulnerability, or if certain factors promote axonal or
neuroprotection.
6.2.1. Brimonidine
Brimonidine is an a2 agonist that has been shown to lower
intraocular pressure and is often used to treat glaucoma. Brimoni-
dine given intraperitoneally and by eye drop following experi-
mental AION improves survival of RGCs.69 In another study,
brimonidine treatment prior to AION is correlated with more sur-
viving axons and RGCs, however, brimonidine treatment 14 days
after AION has no signiﬁcant beneﬁt.58 Although brimonidine has
been postulated to be neuroprotective, the efﬁcacy is relatively
modest. Brimonidine has been shown to increase BDNF level, sug-
gesting itmayworkby improving neurotrophic support.70 Lowering
of the intraocular pressure is also theoretically beneﬁcial because it
may improve perfusion to the eye by lowering resistance.
6.2.2. TrkB receptor activation
Retrogradely transported neurotrophins such as BDNF and its
receptor TrkB are particularly important in the survival of retinal
ganglion cells during development and following injury.5,71,72
When axonal transport is disrupted in optic nerve head ischemia,
exogenous neurotrophic support may signiﬁcantly impact RGC
survival.72 Part of the glaucoma pathogenesis and possibly that of
AION is that there is disruption of the retrogradely transported
BDNF and abnormal accumulation of TrkB receptor at the optic
nerve head.67,71 Other than intravitreal BDNF, which has a very
short half-life, another way to activate the TrkB receptor is to use
monoclonal antibodies that can mimic the action of BDNF.73,74
Another option that has potentially fewer immunologic issues
and is less expensive is the use of small molecule pharmacophores,
Y.J. Liao, J.J. Hwang / Taiwan Journal of Ophthalmology 4 (2014) 9e16 15which have nanomolar afﬁnity for the TrkB receptor75 and can cross
the blood-nerve barrier. There are also published reports of using
gene therapy or stem cell therapy as a chronic source of BDNF.76,77
7. Summary and future studies
Through studies using experimental models of AION, we are
learning about molecular and cellular events that occur at the
retina, optic nerve head, and the posterior optic nervewithin hours,
days, and weeks after ischemia. There are several potential thera-
peutic approaches involving targeting of the inﬂammatory cascade
and promoting survival of the retinal ganglion cell axons and cell
bodies. Successful treatment of human AION may not be possible
without a better understanding of the incipient events leading to
irreversible vision loss, and this must be done with more human
and animal studies. Effective therapy should be given as early as
possible, possibly within hours of onset, and, ultimately, a thera-
peutic cocktail that targets different aspects of the disease may be
most effective. Our current drug development pipeline is failing
conditions such as AION, and efforts to collaborate and perform
rigorous testing of effective therapies will not happen until we
realize that we need to revolutionize the system.
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